Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer

Research output: Contribution to journalReview article

49 Scopus citations

Abstract

Overexpression of the HER2/Neu (ErbB2) proto-oncogene is associated with breast cancer progression and poor patient prognosis. Herceptin (trastuzumab) is a humanized IgG1 against the ectodomain of the HER2 receptor. In combination with chemotherapy, it induces regression of HER2-overexpressing metastatic breast tumors and prolongs patient survival. Single-agent Herceptin in patients with HER2-amplified breast tumors also induces a definite objective response and clinical benefit rates, and is well tolerated. These data suggest that Herceptin is an effective first-line single-agent therapy for a predictable cohort of metastatic breast cancers and can therefore be used as a platform for therapeutic discovery against tumors that overexpress HER2.

Original languageEnglish (US)
Pages (from-to)96-100
Number of pages5
JournalBreast Cancer Research
Volume5
Issue number2
DOIs
StatePublished - Apr 1 2003

Keywords

  • Breast cancer
  • Clinical trials
  • HER2/Neu
  • Herceptin
  • erbB2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this